methods and findings we carried out a phase i-ii safety, tolerability, pharmacokinetic and efficacy trial of ivc combined with chemotherapy in patients whose treating oncologist judged that standard-of-care or off-label chemotherapy offered less than a 33% likelihood of a meaningful response.